Klotho Neurosciences, Inc. (NASDAQ:KLTO) Sees Large Decrease in Short Interest

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 391,815 shares, a drop of 18.8% from the December 31st total of 482,725 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily volume of 648,138 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 648,138 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC purchased a new stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned 0.05% of Klotho Neurosciences at the end of the most recent reporting period. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Klotho Neurosciences Stock Performance

NASDAQ:KLTO traded down $0.01 during mid-day trading on Wednesday, hitting $0.25. The company had a trading volume of 339,728 shares, compared to its average volume of 597,333. The firm has a market cap of $18.68 million, a P/E ratio of -0.79 and a beta of 10.27. The business’s fifty day moving average is $0.36 and its two-hundred day moving average is $0.55. Klotho Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $3.91.

Klotho Neurosciences (NASDAQ:KLTO) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.